人福医药集团股份公司2025 年半年度报告 公司代码：600079 公司简称：人福医药 人福医药集团股份公司 二〇二五年八月 人福医药集团股份公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人杜文涛、主管会计工作负责人杜文涛及会计机构负责人（会计主管人员）何华 琴声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的前瞻性陈述不构成公司对投资者的实质承诺，敬请广大投资者注意投资风 险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细描述可能存在的风险，具体内容详见本报告"第三 ...

Core Viewpoint - Recent management changes at Renfu Pharmaceutical have raised market concerns, particularly with the resignation of key executives and the appointment of a new president amid a significant investment from China Merchants Group [2][4] Management Changes - Three veteran executives, including the long-serving president, have resigned for personal reasons, prompting worries about the stability of the management structure [3][4] - The new president, Du Wentao, has been appointed, while the newly nominated directors from China Merchants lack direct experience in the anesthetics field, raising concerns about their ability to manage the company effectively [5][6] Financial Performance and Strategy - Renfu Pharmaceutical has been undergoing a "core focus" strategy, frequently divesting non-core assets, with significant impairments reported in 2024, including credit impairment of 283 million and asset impairment of 394 million [2][6] - Despite these challenges, the company reported a revenue increase of 3.71% in 2024, reaching 25.435 billion, with the anesthetics segment contributing significantly to overall revenue [8] Research and Development Concerns - The retirement of key R&D personnel has raised concerns about the company's research capabilities, although the company plans to enhance its R&D pipeline and attract global talent [3][6] - The number of high-educated R&D staff has declined, with a notable drop in the number of PhD holders from 202 to 125 [3] Market Position and Future Outlook - Renfu Pharmaceutical is positioned to benefit from the integration with China Merchants, which is expected to enhance its capital operations and investment capabilities [5][6] - The company has achieved breakthroughs in international markets, with its product receiving approval in Germany, indicating potential for overseas expansion [9] - The anesthetics market remains a stronghold for the company, with a focus on maintaining its competitive edge while leveraging new capital resources for growth [9]

Market Overview - The A-share market showed an overall upward trend, with the Shanghai Composite Index closing at 3369.24, up 0.82%, and the Shenzhen Component Index rising 1.72% to 10301.16 [2][6] - The total market capitalization of the Shanghai Composite Index is 6467.64 billion, with a PE ratio of 11.88 and a PB ratio of 1.23 [3] Industry Dynamics - The Fujian Provincial Government issued measures to promote the capital market's service for high-quality development of technology-based enterprises, signaling positive support for regional brokerage differentiation [29][31] - Canalys reported a year-on-year increase of 8.5% in global tablet shipments in Q1 2025, reaching 36.8 million units, driven by demand in the consumer and education sectors [32][33] - The photovoltaic industry chain is experiencing a price decline as the rush for installation nears its end, with significant price drops across various components [36] - The financial asset investment company (AIC) sector is expected to expand, with major banks announcing plans to establish AICs to better support new productive forces [38] - From January to April 2025, nationwide railway fixed asset investment reached 194.7 billion, reflecting a 5.3% year-on-year increase, contributing positively to economic recovery [40] Company Updates - Renowned pharmaceutical company Renfu Pharmaceutical received approval from the German Federal Institute for Drugs and Medical Devices for its hydromorphone injection, which is expected to enhance its international business prospects [44] - Longpan Technology signed a sales agreement for 150,000 tons of lithium iron phosphate, with an estimated total sales amount exceeding 5 billion, indicating strong demand in the battery materials sector [46] - The company ZTE reported a 2024 revenue of 79.02 billion, with a notable increase in international business, reflecting a robust growth trajectory [58][60]